Aktis Oncology (AKTS) vs Amphastar Pharmaceuticals (AMPH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Amphastar Pharmaceuticals is the larger company by market cap ($1.10 billion vs $986.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AKTS | AMPH |
|---|---|---|
| Share price | $17.74 | $25.81 |
| Market cap | $986.69M | $1.10B |
| 1-day change | -1.44% | +1.06% |
| YTD return | — | -3.62% |
| 1-year return | — | -0.65% |
| 5-year return | — | +35.06% |
| P/E ratio (TTM) | — | 15.27 |
| Forward P/E | — | 8.11 |
| EPS (TTM) | $-1.70 | $1.69 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $34.19 | $29.52 |
| 52-week low | $14.72 | $16.65 |
| Distance from 52-week high | -48.11% | -12.57% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +99.49% | -12.82% |
| Average volume | 366.06K | 472.25K |
| Shares outstanding | 53.75M | 42.54M |
| Employees | 79 | 1,976 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Aktis Oncology
AKTS stock →Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company's lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and [225Ac]Ac-AKY-2519 to deliver 225Ac to B7-H3 (CD276) expressing tumors, including prostate, lung and other solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 79 employees
About Amphastar Pharmaceuticals
AMPH stock →Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,976 employees
AKTS vs AMPH FAQ
Which is bigger, Aktis Oncology or Amphastar Pharmaceuticals?
Amphastar Pharmaceuticals (AMPH) is larger, with a market capitalization of $1.10B compared with $986.69M for Aktis Oncology (AKTS).
Are Aktis Oncology and Amphastar Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.